Clinical Trials Browser

Unknown × OTHER_GOV × eribulin × Clear all

NCT05335473 2023-04-06

Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure

Phase 1/2 Unknown

HR Positive HER2 Negative Advanced Breast Cancer